Dr. Reddy's Founder Dismisses Acquisition Talks As Gossip: "We Will Never Sell To An MNC"
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - "It's my life and we will never sell Dr. Reddy's to an MNC," Kallam Anji Reddy, who founded the nearly $2 billion Indian company 25 years ago, told a television news channel in an interview to quell widespread speculation that the firm is the target of multinational companies for a potential acquisition
You may also be interested in...
With Shrinking Market Share, GSK Sells Augmentin, Amoxil U.S. Rights To Dr. Reddy's, Along With Tennessee Manufacturing Site
MUMBAI - Acting on the strategy of hiving off late-stage brands and non-core assets, GlaxoSmithKline Pharma has sold its once marquee anti-bacterial Augmentin and Amoxil brand rights in the U.S. to India's Dr. Reddy's Labs for an undisclosed sum
With Shrinking Market Share, GSK Sells Augmentin, Amoxil U.S. Rights To Dr. Reddy's, Along With Tennessee Manufacturing Site
MUMBAI - Acting on the strategy of hiving off late-stage brands and non-core assets, GlaxoSmithKline Pharma has sold its once marquee anti-bacterial Augmentin and Amoxil brand rights in the U.S. to India's Dr. Reddy's Labs for an undisclosed sum
Piramal Deal Done, Abbott's India Plunge May Fetch Big Returns, But Integration Challenges, Growth Momentum Critical
MUMBAI - Piramal Healthcare Chairman Ajay Piramal redefined the valuation processes for Indian life science companies last week, when he sold his domestic business of predominantly 350 branded generic products to Illinois-based Abbott for $3.72 billion - a jaw-dropping price that is nine times the level of annual sales and 31 times that of earnings